| 2025-12-01 |
详情>>
内部人交易：
Hardy Alexander共交易2笔
|
| 2025-10-28 |
详情>>
股本变动：
变动后总股本19211.43万股
|
| 2025-10-28 |
详情>>
业绩披露：
2025年三季报(累计)每股收益2.06美元,归母净利润3.95亿美元,同比去年增长30.99%
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益2.23美元,归母净利润4.26亿美元,同比去年增长117.64%
|
| 2025-08-04 |
财报披露：
美东时间 2025-08-04 盘后发布财报
|
| 2025-05-02 |
详情>>
业绩披露：
2025年一季报每股收益0.97美元,归母净利润1.86亿美元,同比去年增长109.43%
|
| 2025-04-08 |
股东大会：
将于2025-05-20召开股东大会
会议内容 ▼▲
- 1.To elect the 10 nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To ratify the selection of KPMG LLP (KPMG) as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2025;
3.To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers (NEOs) as disclosed in the Proxy Statement;
4.To approve an amendment to the 2017 Equity Incentive Plan, as amended;
5.To conduct any other business properly brought before the Annual Meeting.
|
| 2025-02-24 |
详情>>
业绩披露：
2022年年报每股收益0.76美元,归母净利润1.42亿美元,同比去年增长320.91%
|
| 2025-02-24 |
详情>>
业绩披露：
2024年年报每股收益2.25美元,归母净利润4.27亿美元,同比去年增长154.62%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益1.59美元,归母净利润3.02亿美元,同比去年增长105.01%
|
| 2024-09-04 |
复牌提示：
2024-09-04 10:30:00 停牌，复牌日期 2024-09-04 13:30:00
|
| 2024-08-05 |
详情>>
业绩披露：
2023年中报每股收益0.57美元,归母净利润1.07亿美元,同比去年增长-28%
|
| 2024-08-05 |
详情>>
业绩披露：
2024年中报每股收益1.03美元,归母净利润1.96亿美元,同比去年增长83.21%
|
| 2024-04-26 |
详情>>
业绩披露：
2024年一季报每股收益0.47美元,归母净利润8866.20万美元,同比去年增长74.35%
|
| 2024-04-09 |
股东大会：
将于2024-05-21召开股东大会
会议内容 ▼▲
- 1.To elect the 11 nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To ratify the selection of KPMG LLP (KPMG) as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers (NEOs) as disclosed in the Proxy Statement;
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2024-02-26 |
详情>>
业绩披露：
2023年年报每股收益0.89美元,归母净利润1.68亿美元,同比去年增长18.43%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.78美元,归母净利润1.47亿美元,同比去年增长3.85%
|
| 2023-04-11 |
股东大会：
将于2023-05-23召开股东大会
会议内容 ▼▲
- 1.To elect the 11 nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To ratify the selection of KPMG LLP (KPMG) as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2023;
3.To approve, on an advisory basis, the frequency of the stockholders’ approval, on an advisory basis, of the compensation of the Company’s Named Executive Officers (NEOs) as disclosed in the Proxy Statement;
4.To approve, on an advisory basis, the compensation of the Company’s NEOs as disclosed in the Proxy Statement;
5.To approve an amendment to the 2017 Equity Incentive Plan, as amended;
6.To conduct any other business properly brought before the Annual Meeting.
|
| 2023-04-11 |
股东大会：
将于2023-05-23召开股东大会
会议内容 ▼▲
- 1.To elect the 11 nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To ratify the selection of KPMG LLP (KPMG) as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2023;
3.To approve, on an advisory basis, the frequency of the stockholders’ approval, on an advisory basis, of the compensation of the Company’s Named Executive Officers (NEOs) as disclosed in the Proxy Statement;
4.To approve, on an advisory basis, the compensation of the Company’s NEOs as disclosed in the Proxy Statement;
5.To approve an amendment to the 2017 Equity Incentive Plan, as amended;
6.To conduct any other business properly brought before the Annual Meeting.
|
| 2022-04-12 |
股东大会：
将于2022-05-24召开股东大会
会议内容 ▼▲
- 1.To elect the 11 nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To ratify the selection of KPMG LLP (KPMG) as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2022;
3.To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers (NEOs) as disclosed in the Proxy Statement;
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-13 |
股东大会：
将于2021-05-25召开股东大会
会议内容 ▼▲
- 1.To elect the 11 nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2021;
3.To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement;
4.To approve an amendment to the 2017 Equity Incentive Plan, as amended;
5.To conduct any other business properly brought before the Annual Meeting.
|
| 2020-04-14 |
股东大会：
将于2020-05-27召开股东大会
会议内容 ▼▲
- 1.To elect the ten nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2020;
3.To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement;
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2019-04-23 |
股东大会：
将于2019-06-04召开股东大会
会议内容 ▼▲
- 1.To elect the ten nominees for Director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2019;
3.To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement;
4.To approve an amendment to the 2017 Equity Incentive Plan;
5.To approve amendments to the Amended and Restated 2006 Employee Stock Purchase Plan;
6.To conduct any other business properly brought before the Annual Meeting.
|
| 2018-04-24 |
股东大会：
将于2018-06-05召开股东大会
会议内容 ▼▲
- 1.To elect the ten nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2018;
3.To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement;
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2017-04-25 |
股东大会：
将于2017-06-06召开股东大会
会议内容 ▼▲
- 1.To elect the nine nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2017;
3.To approve, on an advisory basis, the frequency of the stockholders’ approval, on an advisory basis, of the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement;
4.To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement;
5.To approve the 2017 Equity Incentive Plan;
6.To approve amendments to BioMarin’s Amended and Restated Certificate of Incorporation, as amended, to (i) increase the total number of authorized shares of common stock from 250,000,000 shares to 500,000,000 shares, and (ii) make certain minor administrative changes;
7.To conduct any other business properly brought before the Annual Meeting.
|
| 2016-04-25 |
股东大会：
将于2016-06-06召开股东大会
会议内容 ▼▲
- 1.To elect the eight nominees for director to serve until the next Annual Meeting and until their successors are duly elected and qualified;
2.To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers (NEOs) as defined below and disclosed in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement);
3.To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2016;
4.To consider and vote upon a stockholder proposal requesting that BioMarin issue a sustainability report describing BioMarin’s environmental, social and governance performance, if properly presented at the meeting;
5.To conduct any other business properly brought before the Annual Meeting.
|